Geneva Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Geneva Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$3.67M	Sell	65,925 -465,654	-88%	-$25.3M	0.06%	140
2017 Q1	$28.9M	Sell	531,579 -21,900	-4%	-$1.2M	0.52%	60
2016 Q4	$32.3M	Sell	553,479 -58,164	-10%	-$3.18M	0.63%	52
2016 Q3	$33M	Sell	611,643 -479,551	-44%	-$30.8M	0.62%	55
2016 Q2	$80.3M	Buy	1,091,194 +115,324	+12%	+$8.15M	1.59%	14
2016 Q1	$62.3M	Buy	975,870 +448,853	+85%	+$28.3M	1.25%	23
2015 Q4	$36.3M	Buy	527,017 +54,248	+11%	+$3.58M	0.7%	52
2015 Q3	$28M	Sell	472,769 -14,112	-3%	-$895K	0.56%	57
2015 Q2	$32.4M	Buy	486,881 +10,961	+2%	+$722K	0.58%	59
2015 Q1	$30.7M	Buy	475,920 +443,210	+1,355%	+$27.7M	0.56%	61
2014 Q4	$1.93M	Sell	32,710 -878	-3%	-$49.5K	0.04%	203
2014 Q3	$1.72M	Buy	33,588 +957	+3%	+$47.8K	0.03%	210
2014 Q2	$1.58M	Buy	32,631 +3,091	+10%	+$152K	0.03%	237
2014 Q1	$1.53M	Buy	29,540 +221	+0.8%	+$11.8K	0.03%	236
2013 Q4	$1.56M	Buy	29,319 +645	+2%	+$32.9K	0.03%	195
2013 Q3	$1.33M	Buy	28,674 +2,251	+9%	+$98.8K	0.03%	216
2013 Q2	$1.18M	Buy	+26,423	New	+$1.15M	0.03%	202

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geneva Advisors's BMY Position: Q2 2017 in Review

Geneva Advisors reduced its Bristol-Myers Squibb (BMY) stake by 88% in Q2 2017, selling an estimated $25.3M and leaving 65,925 shares worth $3.67M. The position accounts for 0.06% of the portfolio, ranked #140.

Geneva Advisors first reported a position in BMY in Q2 2013 and has held it in 17 quarters since. The position peaked at $80.3M in Q2 2016. 1,594 funds tracked by Wall St. Rank hold BMY as of Q2 2017.

Geneva Advisors held 65,925 shares of Bristol-Myers Squibb worth $3.67M as of Q2 2017.
Geneva Advisors sold 465,654 Bristol-Myers Squibb shares in Q2 2017, an estimated $25.3M.
Bristol-Myers Squibb made up 0.06% of Geneva Advisors's portfolio in Q2 2017, its #140 holding.
Geneva Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 17 quarters since.
Geneva Advisors's Bristol-Myers Squibb position peaked at $80.3M in Q2 2016.
1,594 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.